Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2018

View Archived Issues

Alkahest obtains grant to develop new Parkinson's disease treatment

Pain Therapeutics resubmits Remoxy ER NDA

Novel mutation in GLA gene identified for Fabry disease

Phase I study begins of AB-569 for antibiotic-resistant bacterial lung infections

CureVac receives two new grants from the Bill & Melinda Gates Foundation

First patient treated in phase I study of NantKwest's HER2.taNK

Study predicts human doses of RVT-801 for treating Farber disease

Advaxis submits conditional MAA for axalimogene filolisbac in E.U.

Researchers develop Drosophila model of multiple sulfatase deficiency

Interim data support continuation of clinical trial testing MEI Pharma's ME-344

Durvalumab demonstrates activity in phase II CONDOR trial

In situ vaccination with a TLR ligand and anti-OX40 antibody eliminates tumors

Mallinckrodt's acquisition of Sucampo completed

Asavi identifies novel viral NS5B inhibitors

Astellas acquires Universal Cells

Moleculin Biotech and Emory University to collaborate on development of medulloblastoma treatment

Harvard College patents new vaccines for bacterial infections

FDA grants priority review to Rituxan sBLA in pemphigus vulgaris

Vaxart completes merger with Aviragen Therapeutics

Auspherix receives grant to work on organogold antibacterial compounds for respiratory infections

European Commission approves trastuzumab biosimilar Herzuma

Poseida Therapeutics patent describes MUC1-binding CARs for cancer

Merck & Co. stops APECS study of verubecestat based on DMC recommendation

Santen reports results from phase I/II study of DE-122 for AMD

Aduro BioTech Holdings Europe presents anti-PD-1 MAbs

First patient dosed in phase I/IIa study of Bicycle Therapeutics' BT-1718

IGNITE3 trial of eravacycline in cUTI trial does not meet coprimary endpoints

OBI Pharma discovers novel antibodies for cancer

Lee's licenses development and commercialization rights to GCC-4401C in China and SE Asia

Mologen enters lefitolimod agreement with Oncologie

We want your opinion - complete the TRDN user survey

Cabozantinib shows encouraging results in phase II study in differentiated thyroid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.